不同淋巴结清扫方式对cIA期肺腺癌患者围手术期的影响分析
Analysis of the Influence of Different Lymph Node Dissection Methods on the Perioperative Period of cIA Stage Lung Adenocarcinoma Patients
DOI: 10.12677/HJS.2021.104010, PDF,   
作者: 衣腾飞*, 李 烁, 邵盛腾, 刘玉洪#:青岛大学附属医院胸外科,山东 青岛;秦 坤:青岛大学附属医院急诊科,山东 青岛;高俊琼:青岛大学附属医院麻醉科,山东 青岛
关键词: cIA期肺腺癌系统性纵隔淋巴结切除术淋巴结采样叶特异性淋巴结清扫术Clinical Stage IA Lung Adenocarcinoma Systematic Mediastinal Lymph Node Dissection Lymph Node Sampling Lobe-Specific Lymph Node Dissection
摘要: 目的:研究系统性纵隔淋巴结切除术(systematic mediastinal lymph node dissection, SMLD)、淋巴结采样(lymph node sampling, LNS)和叶特异性淋巴结清扫术(lobe-specific lymph node dissection, L-SND)对胸腔镜肺癌切除术患者的影响,进而探索临床IA期(Clinical Stage IA, cIA)肺腺癌患者最佳淋巴结清扫方式。方法:采用回顾性队列研究,利用“医渡云”系统收集603例2015年6月~2019年6月在青岛大学附属医院胸外科行胸腔镜手术的cIA期肺腺癌患者的临床资料。采用IBM SPSS 23.0软件完成统计学分析,计量资料的比较采用单因素方差分析或Kruskal-Wallis H检验;计数资料的比较采用χ2检验或Fisher’s确切概率法。单因素logistic回归分析pN的危险因素,并将有统计学意义的因素纳入多因素logistic回归分析。结果:肿瘤的大小、CTR、组织学类型、pN、术后并发症、置管时间以及住院时间在SMLD、LNS和L-SND三组间具有统计学差异,且多因素Logistic回归分析显示吸烟史(OR = 2.989,95%CI = 1.436~6.219,P = 0.03)、CTR (OR = 0.043,95%CI = 0.004~0.426,P = 0.007)是pN的独立危险因素。结论:CTR = 0或术中快速冰冻病理示AIS的T1a-3aN0M0患者可不进行淋巴结清扫;0 < CTR ≤ 0.5或术中快速冰冻病理示MIA的T1a-3aN0M0或0.5 < CTR < 1的T1aN0M0患者推荐LNS或L-SND;而0.5 < CTR ≤ 1的T2a-3aN0M0或CTR = 1的T1a-3aN0M0或术中快速冰冻病理示IDA尤其是PPA、MPA的患者则推荐SMLD。
Abstract: Objective: To study the effects of systematic mediastinal lymph node dissection (SMLD), lymph node sampling (LNS) and lobe-specific lymph node dissection (L-SND) on patients underwent vid-eo-assisted thoracoscopic surgery, and then explore an optimal lymph node dissection for patients with clinical stage IA (cIA) lung adenocarcinoma. Methods: In this retrospective cohort study, from June 2015 to June 2019, the clinical date of 603 patients with cIA lung adenocarcinoma who underwent video-assisted thoracoscopic surgery in the department of Thoracic Surgery of The Affiliated Hospital of Qingdao University were collected by using the “Medical Du Yun” system. IBM SPSS 23.0 statistical software was used to complete the statistical analysis, the measurement data were compared by one-way ANOVA or Kruskal-Wallis H test, and the counting data were compared by chisquare test or Fisher exact probability test. Univariate analysis was performed on the risk factors of pN, then the factors with statistically significant were included in multivariate logistic regression analysis. Results: There were statistically significant differences in tumor size, CTR, histo-logical type, pN, postoperative complications, time of intubation and time of hospital stay among SMLD, LNS and L-SND groups. Multivariate logistic regression analysis showed that smoking (OR = 2.989, 95%CI = 1.436~6.219, P = 0.03) and CTR (OR = 0.043, 95%CI = 0.004~0.426, P = 0.007) were independent risk factors of pN. Coclusions: For T1a-3aN0M0 patients with CTR = 0 or AIS, lymph node dissection may not be performed; LNS or L-SND is recommended when T1a- 3aN0M0 patients with 0 < CTR ≤ 0.5 or MIA and T1aN0M0 patients with 0.5 < CTR < 1; however, SMLD is recom-mended for T2a-3aN0M0 with 0.5 < CTR ≤ 1 or T1a-3aN0M0 with CTR = 1, or patients with IDA, especially PPA and MPA, as shown by intraoperative rapid freezing pathology.
文章引用:衣腾飞, 李烁, 秦坤, 邵盛腾, 高俊琼, 刘玉洪. 不同淋巴结清扫方式对cIA期肺腺癌患者围手术期的影响分析[J]. 外科, 2021, 10(4): 54-62. https://doi.org/10.12677/HJS.2021.104010

参考文献

[1] Bray, F., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] Barta, J.A., Powell, C.A. and Wisnivesky, J.P. (2019) Global Epidemiol-ogy of Lung Cancer. Annals of Global Health, 85, 8. [Google Scholar] [CrossRef] [PubMed]
[3] Lardinois, D., et al. (2006) ESTS Guidelines for Intraoperative Lymph Node Staging in Non-Small Cell Lung Cancer. European Journal of Cardio-Thoracic Surgery, 30, 787-792. [Google Scholar] [CrossRef] [PubMed]
[4] Darling, G.E., et al. (2011) Randomized Trial of Mediastinal Lymph Node Sampling versus Complete Lymphadenectomy during Pulmonary Resec-tion in the Patient with N0 or N1 (Less than Hilar) Non-Small Cell Carcinoma: Results of the American College of Sur-gery Oncology Group Z0030 Trial. The Journal of Thoracic and Cardiovascular Surgery, 141, 662-670. [Google Scholar] [CrossRef] [PubMed]
[5] David, E.A., et al. (2017) Does Lymph Node Count Influence Survival in Surgically Resected Non-Small Cell Lung Cancer? The Annals of Thoracic Surgery, 103, 226-235. [Google Scholar] [CrossRef] [PubMed]
[6] Mountain, C.F. (1997) Revisions in the International System for Staging Lung Cancer. Chest, 111, 1710-1717. [Google Scholar] [CrossRef] [PubMed]
[7] Adachi, H., et al. (2017) Lobe-Specific Lymph Node Dissection as a Standard Procedure in Surgery for Non-Small Cell Lung Cancer: A Propensity Score Matching Study. Journal of Tho-racic Oncology, 12, 85-93. [Google Scholar] [CrossRef] [PubMed]
[8] Dezube, A.R., et al. (2020) Analysis of Lymph Node Sampling Minimums in Early Stage Non-Small-Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery. [Google Scholar] [CrossRef] [PubMed]
[9] Wankhede, D. (2021) Evaluation of Eighth AJCC TNM Sage for Lung Cancer NSCLC: A Meta-Analysis. Annals of Surgical Oncology, 28, 142-147. [Google Scholar] [CrossRef] [PubMed]
[10] Zhang, Y., et al. (2020) Segment Location and Ground Glass Opacity Ratio Reliably Predict Node-Negative Status in Lung Cancer. The Annals of Thoracic Surgery, 109, 1061-1068. [Google Scholar] [CrossRef] [PubMed]
[11] Hughes, M.J., Chowdhry, M.F., Woolley, S.M. and Walker, W.S. (2011) In Patients Undergoing Lung Resection for Non-Small Cell Lung Cancer, Is Lymph Node Dissection or Sampling Superior? Interactive CardioVascular and Thoracic Surgery, 13, 311-315. [Google Scholar] [CrossRef] [PubMed]
[12] Maniwa, T., et al. (2013) Recurrence of Mediastinal Node Cancer after Lobe-Specific Systematic Nodal Dissection for Non-Small-Cell Lung Cancer. European Journal of Car-dio-Thoracic Surgery, 44, e59-e64. [Google Scholar] [CrossRef] [PubMed]
[13] Yoon, H.Y., et al. (2018) Prognosis of Multi-Level N2-Positive Non-Small Cell Lung Cancer According to Lymph Node Staging Using Endobronchial Ultrasound-Transbronchial Bi-opsy. Thoracic Cancer, 9, 684-692. [Google Scholar] [CrossRef] [PubMed]
[14] Aokage, K., et al. (2010) Subcarinal Lymph Node in Upper Lobe Non-Small Cell Lung Cancer Patients: Is Selective Lymph Node Dissection Valid? Lung Cancer, 70, 163-167. [Google Scholar] [CrossRef] [PubMed]
[15] Deng, H.Y., et al. (2020) Lobe-Specific Lymph Node Dissec-tion for Clinical Early-Stage (cIA) Peripheral Non-Small Cell Lung Cancer Patients: What and How? Annals of Surgical Oncology, 27, 472-480. [Google Scholar] [CrossRef] [PubMed]
[16] Wu, Y., et al. (2020) Metastatic Patterns of Mediastinal Lymph Nodes in Small-Size Non-Small Cell Lung Cancer (T1b). Frontiers in Surgery, 7, Article ID: 580203. [Google Scholar] [CrossRef] [PubMed]
[17] Okada, M., et al. (1998) Proposal for Reasonable Mediastinal Lymphadenectomy in Bronchogenic Carcinomas: Role of Subcarinal Modes in Selective Dissection. The Journal of Thoracic and Cardiovascular Surgery, 949-953. [Google Scholar] [CrossRef
[18] Tsitsias, T., et al. (2021) New N1/N2 Classification and Lobe Specific Lymphatic Drainage: Impact on Survival in Patients with Non-Small Cell Lung Cancer Treated with Sur-gery. Lung Cancer, 151, 84-90. [Google Scholar] [CrossRef] [PubMed]
[19] Haruki, T., et al. (2015) Mediastinal Nodal Involvement in Pa-tients with Clinical Stage I Non-Small-Cell Lung Cancer: Possibility of Rational Lymph Node Dissection. Journal of Thoracic Oncology, 10, 930-936. [Google Scholar] [CrossRef
[20] Cao, J., et al. (2018) Prognostic Impact of Lymphadenecto-my on Outcomes of Sublobar Resection for Stage IA Non-Small Cell Lung Cancer Google Scholar] [CrossRef] [PubMed]
[21] 杨耀湘. 非小细胞肺癌患者ALK、EGFR、KRAS基因的检测及临床病理特征[J]. 中国现代药物应用, 2018, 12(8): 219-220.
[22] Hishida, T., et al. (2018) A Randomized Phase III Trial of Lobe-Specific vs. Systematic Nodal Dissection for Clinical Stage I-II Non-Small Cell Lung Cancer (JCOG1413). Japanese Journal of Clinical Oncology, 48, 190-194. [Google Scholar] [CrossRef] [PubMed]